April 28th 2024
During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for patients with hepatocellular carcinoma, looking in particular at what data is available for those with Child-Pugh B and C status who have poorer outcomes and have limited data from prospective clinical trials.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Cabozantinib Plus Atezolizumab Reduces Risk of Disease Progression or Death in Advanced HCC
June 28th 2021The combination of cabozantinib and atezolizumab demonstrated improvement in both progression-free and overall survival compared with sorafenib, in patients with untreated advanced hepatocellular carcinoma.
Read More
ODAC Panel Approves 4 of 6 Anti–PD-1/PD-L1 Drugs in Accelerated Approval Program
June 16th 2021An FDA Oncologic Drugs Advisory Committee meeting resulted in continued approval for 4 of 6 indications that were discussed, although all 6 indications did not demonstrate clinical benefit in confirmatory studies. The meeting, held April 27-29, evaluated anti–PD-1/PD-L1 drugs that received accelerated approvals through the FDA’s accelerated approval program, a nearly 30-year-old initiative to expedite the approval process.
Read More
Updated Results Show Encouraging Early Signs for Regorafenib Plus Pembrolizumab in advanced HCC
June 10th 2021An updated analysis, presented at the 2021 ASCO Annual Meeting, showed encouraging signs for the combination of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma.
Read More
Lenvatinib With Toripalimab and HAIC May Offer a New Frontline Option for Advanced HCC Treatment
June 9th 2021Results from the phase 2 LTHAIC study showed that adding toripalimab and hepatic arterial infusion chemotherapy to lenvatinib achieved robust and durable responses in patients with advanced hepatocellular carcinoma.
Read More
ODAC Opposes Ongoing FDA Approval of Nivolumab for HCC in Patients Pretreated With Sorafenib
April 29th 2021The FDA’s Oncologic Drug Advisory Committee voted 5 to 4 against the continued accelerated approval of nivolumab for the treatment of patients with hepatocellular carcinoma who were previously treated with sorafenib.
Read More
Regorafenib/Nivolumab Proof of Concept Suggested in Third-Line, Refractory HCC
March 28th 2021Half of all patients with hepatocellular carcinoma treated with the combination of regorafenib and nivolumab following progression on 2 lines of chemotherapy achieved disease control, according to initial results from a phase 2 proof-of-concept trial.
Read More
Sintilimab With SBRT Leads to 100% Disease Control in Oligometastatic HCC
March 25th 2021In a single-arm study, 100% of patients treated with sintilimab plus stereotactic body radiotherapy who had oligometastases of hepatocellular carcinoma achieved disease control and were alive and progression free at 6 months.
Read More
Doctors Debate: Is Systemic or Liver-Directed Therapy Best for Hepatocellular Carcinoma?
March 5th 2021As part of the virtual 17th Annual Meeting of the International School of Gastrointestinal Oncology, a debate ensued around whether liver-directed or systemic therapy is best for the treatment of patients with HCC.
Read More